![]() |
|
|
Vol. 280, Issue 3, 1159-1169, 1997
Department of Anesthesia and Critical Care, The Pritzker School of
Medicine, The University of Chicago, Chicago, Illinois
The purposes of this study were to characterize the subjective,
psychomotor and physiological effects of nalbuphine in healthy non-drug
abusing volunteers and to compare and contrast the effects of
equianalgesic doses of nalbuphine and morphine. Subjects (12 males, 4 females) without histories of opiate dependence were injected in an
upper extremity vein with 0, 2.5, 5.0 or 10 mg/70 kg nalbuphine, or
with 10 mg/70 kg morphine, using a randomized, double-blind, crossover
design. The 10-mg doses of nalbuphine and morphine are considered
equianalgesic and are doses commonly given for relief of postoperative
pain. Subjective effects of nalbuphine included increased scores on the
Pentobarbital-Chlorpromazine-Alcohol Group scale and the Lysergic Acid
Diethylamide scale of the Addiction Research Center Inventory;
increased adjective checklist ratings of "nodding," "numb" and
"sweating"; increased visual analog scale ratings of "coasting or
spaced out," "high" and "sleepy" and increased "feel drug
effect" and drug-liking ratings. Ten milligrams of nalbuphine had
subjective effects similar, and similar in magnitude, to those of 10 mg
of morphine. Nalbuphine produced exophoria and impairment on the Digit
Symbol Substitution Test in a dose-related fashion. Ten milligrams of
morphine produced exophoria but did not affect performance on the Digit
Symbol Substitution Test. Both nalbuphine and morphine induced miosis
and decreases in respiration rate. The results of the present study
demonstrate that 2.5 to 10 mg nalbuphine had orderly, dose-related
effects on subjective, psychomotor and physiological variables. The
results also indicate that 10 mg of nalbuphine produces a profile of
subjective, psychomotor and physiological effects similar to that of an
equianalgesic dose of morphine (10 mg). The similarity in profiles
between drugs at this dose is consistent with both infrahuman studies,
which suggests that nalbuphine is a mu agonist, and studies
with nondependent opioid abusers, in which relatively low doses of
nalbuphine (such as 10 mg) produce morphine-like effects.
This article has been cited by other articles:
![]() |
M Woollard, T Jones, K Pitt, and N Vetter Hitting them where it hurts? Low dose nalbuphine therapy Emerg. Med. J., November 1, 2002; 19(6): 565 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Zacny, J. L. Hill, M. L. Black, and P. Sadeghi Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Pentazocine and Morphine in Normal Volunteers J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1197 - 1207. [Abstract] [Full Text] |
||||
![]() |
G. Bot, A. D. Blake, S. Li, and T. Reisine Fentanyl and its Analogs Desensitize the Cloned Mu Opioid Receptor J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1207 - 1218. [Abstract] [Full Text] |
||||
![]() |
J. P. Zacny, K. Conley, and J. Galinkin Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Buprenorphine and Morphine in Healthy Volunteers J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1187 - 1197. [Abstract] [Full Text] |
||||